کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5632209 1406529 2016 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Use of the six-minute walk test to characterize golden retriever muscular dystrophy
ترجمه فارسی عنوان
استفاده از تست شش دقیقه ای پیاده روی برای تشخیص دیستروفی عضلانی رتینول طلایی
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی علوم اعصاب تکاملی
چکیده انگلیسی


- GRMD dogs walked shorter absolute and height-adjusted distances on the 6MWT at 6 and 12 months of age.
- 6MWT results correlated with other functional outcome parameters for all dogs, but not GRMD alone.
- The percent change in CK after the 6MWT was greater in GRMD versus normal/carrier dogs at 6 months.
- An 80% increase in distance walked or 55% decrease in CK would achieve a power of 0.80 if six GRMD dogs were assessed at 6 months.

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder in which loss of the dystrophin protein causes progressive skeletal/cardiac muscle degeneration and death within the third decade. For clinical trials and supportive animal studies, DMD disease progression and response to treatment must be established using outcome parameters (biomarkers). The 6-minute walk test (6MWT), defined as the distance an individual can walk in 6 minutes, is commonly used in DMD clinical trials and has been employed in dogs to characterize cardiac and respiratory disease severity. Building on methods established in DMD and canine clinical studies, we assessed the 6MWT in dogs with the DMD genetic homolog, golden retriever muscular dystrophy (GRMD). Twenty-one cross-bred golden retrievers were categorized as affected (DMD mutation and GRMD phenotype), carrier (female heterozygous for DMD mutation and no phenotype), and normal (wild type DMD gene and normal phenotype). When compared to grouped normal/carrier dogs, GRMD dogs walked shorter height-adjusted distances at 6 and 12 months of age and their distances walked declined with age. Percent change in creatine kinase after 6MWT was greater in GRMD versus normal/carrier dogs at 6 months, providing another potential biomarker. While these data generally support use of the 6MWT as a biomarker for preclinical GRMD treatment trials, there were certain limitations. Results of the 6MWT did not correlate with other outcome parameters for GRMD dogs when considered alone and an 80% increase in mean distance walked would be necessary to achieve satisfactory power.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Neuromuscular Disorders - Volume 26, Issue 12, December 2016, Pages 865-872
نویسندگان
, , , , , , , , , ,